anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pharmaceutical tablet properties, including surface roughness, gloss and temperature, are determined in real-time using Raman spectroscopy. A plurality of coated pharmaceutical tablets are provided having a distribution of known values of a surface property to be modeled. The Raman spectrum of each coated tablet is acquired to generate a distribution of Raman spectra. A correlative model is then developed based upon the distribution of the acquired Raman spectra relative to the distribution of the known values of the measured property. The Raman spectrum of a pharmaceutical tablet is then acquired during and/or after a coating process, and the value of the surface property of the tablet is determined using the correlative model. The steps associated with model development are carried out off-line, whereas the step or steps associated with acquiring the Raman spectra of the pharmaceutical tablet during (preferable) or after online coating process(es) are carried out on-line using a remote, fiber-coupled probe.
The COVID-19 pandemic placed a significant burden on healthcare resources, limiting care to emergent and essential services only. The objective of this study was to describe the effect of the COVID-19 pandemic on the diagnosis and progression of oral cancer lesions in Montreal, Canada. A retrospective analysis of health records was performed. Patients presenting for a new oncology consultation for an oral lesion suspicious for cancer between March 2018 and March 2022, within the Department of Oral and Maxillofacial Surgery of the McGill University Health Center, were included. Data was collected on sociodemographic characteristics, oral cancer risk behaviors of study participants, oral cancer delays, tumor characteristics, and clinical management. A total of 190 patients were included, 91 patients from the pre-pandemic period and 99 from the pandemic period. The demographic characteristics of the patients in the two periods were comparable. There was no significant difference in the patient, professional, or treatment delay between the two periods. There was a non-significant increase in pathologic tumor size during the pandemic, but the pathologic staging and postoperative outcomes were comparable to those of the pre-pandemic cohort. The results indicate that emergent care pathways for oral cancer treatment were efficiently maintained despite the pandemic shutdown of services.
Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
PURPOSE: A pharmaceutical composition containing MIC-1 gene or expression protein thereof is provided to be used for wound healing as a therapeutic agent. CONSTITUTION: A pharmaceutical composition for wound healing contains MIC-1(macrophage inhibitory cytokine-1) gene or expression protein thereof as an active ingredient. The MIC-1 gene encodes an amino acid of sequence number 2 or 7. The MIC-1 gene is inserted to a recombinant vector. The MIC-1 protein has an amino acid sequence of sequence number 2 or 7. The MIC-1 protein is expressed from the expression vector.
Cytokine storms, which result from an abrupt, acute surge in the circulating levels of different pro-inflammatory cytokines, are one of the complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to assess the effect of exosomes on the release of pro-inflammatory cytokines in patients with coronavirus disease 2019 (COVID-19) and compare it with a control group. The cytokines evaluated in this study were TNF-α, IL-6, IL-17, and IFN-γ. The study compared the levels of these pro-inflammatory cytokines in the peripheral blood mononuclear cells (PBMCs) of five COVID-19 patients in the intensive care unit, who were subjected to both inactivated SARS-CoV-2 and exosome therapy, with those of five healthy controls. The cytokine levels were quantified using the ELISA method. The collected data was analyzed in SPSS Version 26.0 and GraphPad Prism Version 9. According to the study findings, when PBMCs were exposed to inactivated SARS-CoV-2, pro-inflammatory cytokines increased in both patients and healthy controls. Notably, the cytokine levels were significantly elevated in the COVID-19 patients compared to the control group P-values were < 0.001, 0.001, 0.008, and 0.008 for TNF-α, IL-6, IL-17, and IFN-γ, respectively. Conversely, when both groups were exposed to exosomes, there was a marked reduction in the levels of pro-inflammatory cytokines. This suggests that exosome administration can effectively mitigate the hyperinflammation induced by COVID-19 by suppressing the production of pro-inflammatory cytokines in patients. These findings underscore the potential safety and efficacy of exosomes as a therapeutic strategy for COVID-19.
On day 1 (Visit 1), the research subject will present to the Translational and Clinical Research Center (TCRC) after an overnight fast. We will obtain informed consent, check vital signs, take anthropometric measurements, and draw fasting blood work through an intravenous catheter. The subject will then be provided a standard mixed meal to be consumed within 30 minutes. Additional blood will be drawn at the time of meal completion (0 minutes), as well as 5, 15, 30, 60, 90, and 120 minutes following the meal. During study days 3-15, the subject will take 7 mg of oral semaglutide once daily. On day 16 (Visit 2), the research subject will return to the TCRC. During this visit, the subject will take the final (14th) dose of semaglutide, receive fasting blood work, and receive another mixed meal with subsequent blood draws at several time points over 120 minutes.
ABI-007 is administered on days 1, 8 and 15 at 125 mg/m\^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
The invention belongs to the technical field of drug sustained and controlled release carrier materials, and particularly relates to a PVA-GG-based double-layer heterogeneous microgel delivery system and application thereof in preparation of colonitis. The bilayer heterogeneous microgel delivery system: the inner layer is made of polyvinyl alcohol (PVA) and Guar Gum (GG), the outer layer is modified by a layer of SA hydrogel, the outermost layer of CS and SA are modified by polyelectrolyte membranes, and curcumin Cur is used as an experimental drug for carrying the drug. The double-layer microgel has different inner and outer matrix materials, so that the double-layer microgel can serve as a delivery system with multiple functions. Is helpful for improving the solubility and the absorption performance of curcumin. The hydrogel can effectively reduce the burst release and premature release behaviors of Cur anti-inflammatory drugs in the gastrointestinal tract through oral administration. The in vivo pharmacodynamics experiment result shows that CUR@gels can be effectively accumulated at the colon part, so that the inflammation condition is relieved, the weight of a mouse is reduced, the colon shortening is improved, and the inflammation level is reduced.
The biologically degradating biologically compatible microparticles are produced according to a method consisting of the followiong. The microparticles including a biologically degradating, biologically compatible polymer matrix containing active (pharmaceutical or diagnostical) agent and organic solvent get into contact with a system of water solvent. As a result of this the organic solvent content in the microparticles is reduced to 2 wt.%. The solvents should have higher temperature from 25 to 40 degrees C for the time they are in contact with the microparticles and include water and solvent mixing with it for the organic solvent. At the end of the process the microparticles are sparated from the water solvent system. 17 claims, 4 figures
Incisional hernias are one of the most frequent complications in abdominal surgery. In Germany, 44.000 incisional hernia repairs per year are performed. Incisional hernia repair is not a low risk operation associated with high recurrence rate and high percentage of postoperative pain. Treatment of incisional hernias represents a significant surgical and socioeconomic problem. Until now, surgical treatment is recommended for patients with incisional hernia independent of symptoms due to the risk of an acute incarceration with serious complications. Studies defining the exact indications for incisional hernia repair and describing the natural course of an incisional hernia including the risk of an acute incarceration are not available to date. Randomized controlled trials having been performed in the past few years show that observation is a reasonable option in mildly symptomatic inguinal hernias. In this study, watchful waiting vs. surgical repair of oligosymptomatic incisional hernias are compared in a prospective-randomized setting for the first time.

The primary endpoint is pain during normal activities measured on the Surgical Pain Scales (SPS) after 24 months follow-up. SPS are a numeric analog scale (NAS) from 0 (no pain) to 150 (maximal pain). The primary endpoint will be dichotomized to no/minimal pain (SPS 0-30) and pain interfering with everyday activities (SPS \> 30). Watchful waiting is non-inferior to surgical repair in case the upper border of the 95 % confidence interval will not include the value of 2.

Secondary outcomes are pain and discomfort during during sports, at rest, patient satisfaction, quality of life, and the frequency of incarceration. The investigators hypothesize that pain intensity during everyday activities is not different in the compared groups and that incarceration frequency is low. If this was the case, a watchful waiting strategy could be applied in oligosymptomatic incisional hernias and risks and costs for surgery could be saved.
PCT No. PCT/FR93/00876 Sec. 371 Date Apr. 28, 1995 Sec. 102(e) Date Apr. 28, 1995 PCT Filed Sep. 13, 1993 PCT Pub. No. WO94/06472 PCT Pub. Date Mar. 31, 1994The invention concerns the use, in the induction of an immune response, of a synthetic microparticle polymer carrying on the surface one or more covalently bonded proteins capable of carrying one or more epitopes, the densities of the protein(s) on the surface of the microparticles, and their molecular weights, being adjusted so as to direct the immune response to the induction of a humoral and cellular response or to the induction of a largely cellular response. Said microparticles have an average diameter of approximately 0.25 to 1.5  mu m.
FIELD: drug technology. SUBSTANCE: native dirt is diluted with water at ratio = (2: 0.9)-(2: 1.1) and poured into extractor apparatus where cold sterilization is carried out in an aqueous medium under pressure 66 atm for 15-20 min followed by pressure drop to atmospheric value at rate above 5 atm/s. Then extractor content is combined with the main extraction line including extractor, evaporator, condenser and accumulating capacity. The diluted dirt is extracted by circle continuous cycle involving CO 2 -extraction, miscella pouring off into evaporator, evaporation of CO 2  and its the following condensing in condenser and the repeated feeding through accumulating capacity into extractor. After cycle termination of one portion of the diluted dirt (cycle time is 3-4 h) evaporator is detached from extractor, CO 2  is evaporated and extract is poured off from evaporator. The spent diluted dirt is settled firstly for 10-15 min, then extract content is separated from the main extraction line by high pressure gate and the diluted dirt is removed. EFFECT: improved method of preparing, ecology safety, decreased solvent consumption. 2 cl
Esophageal cancer is the sixth most common cause of cancer death worldwide, killing over 380,000 people each year. Over 80% of esophageal cancers occur in developing countries, where the great majority of cases are squamous cell carcinomas. Esophageal cancer is characterized by striking geographic variation in incidence. One remarkable high-risk area, called the Central Asian Esophageal Cancer Belt, stretches from the Caspian Sea across Central Asia to northern China and includes focal areas with recorded incidence rates greater than 100/10s/year in both genders. For the past 20 years, D CEG investigators have studied esophageal and gastric cancer in one of these extremely high-risk areas, Linxian, China, at the eastern end of the Belt. While these studies have discovered new risk factors for esophageal cancer in this region, they have produced an incomplete explanation of the etiology of this disease. Now we have the opportunity to perform similar studies in another of these extremely high-risk areas, Golestan Province, Iran, at the other end of the high-risk Belt. The people of Golestan, in northeastern Iran, are geographically, culturally and ethnically quite different from the people of Linxian, and they appear to be similar only in their extraordinarily high rates of esophageal cancer. Performing similar studies in these two exceptional populations will give us a better chance to identify important new modifiable risk factors for esophageal cancer in both places.

Our cohort study is a collaboration between the Digestive Disease Research Center of Tehran University of Medical Sciences (DDRC), the International Agency for Research on Cancer (IARC), and DCEG. The study has recruited 50,000 adults in three administrative districts of eastern Golestan Province. Baseline assessments included lifestyle questionnaire, a semi-quantitative food frequency questionnaire, and collection of blood, hair, nails and urine. Follow up will includes active surveillance by a study team, aided by a comprehensive health network in the rural areas, a GI referral clinic in the largest town, and a provincial cancer registry. The main hypotheses include dietary hypotheses (low consumption of fruits and vegetables, high consumption of hot tea), exposure to potential carcinogens (tobacco, PAHs from non-tobacco sources), novel exposures (opium, animal contact), and genetic susceptibility. Some cross sectional and a few total mortality analyses have been completed. Annual follow-up is ongoing.
Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
A system and method is disclosed for guiding an invasive medical device with radiation absorbing markers. The invasive medical device can include markers with different radiation absorbing properties relative to other portions of the invasive medical device. An imaging device can generate images of the invasive medical device within a patient. A trained model for the invasive medical device can be trained on annotated images of the invasive medical device annotated with marker information identifying the markers and spatial information for the invasive medical device. An imaging computer system can apply the trained model to images of the invasive medical device within the patient including depictions of the markers to determine current spatial information of the invasive medical device inside the patient. The images of the invasive medical device and visual spatial information representing the spatial information of the invasive medical device can be outputted to a display.
BACKGROUND: Jaffe-Campanacci syndrome is a rare syndrome, characterized by multiple non-ossifying fibromas (NOF) and cafe-au-lait patches. The name was coined in 1982 by Mirra after Jaffe who first described the case in 1958. Although it's suggested there is a relation with Neurofibromatosis type 1, there is still no consensus on whether Jaffe-Campanacci syndrome is a subtype or variant of neurofibromatosis-1(NF-1).
CASE PRESENTATION: In this article, we present a case series of 2 patients. The first case is a 13-year-old male with Jaffe-Campanacci syndrome who presented with a distal femur fracture. His father had positive features of both Jaffe-Campanacci syndrome and NF-1, while his sister only had features of NF-1, so we presented both.
CONCLUSION: Jaffe-Campanacci has a clear relationship with type 1 neurofibromatosis, which still has to be genetically established. Due to the presence of several large non-ossifying fibromas of the long bones, it is linked to a significant risk of pathological fractures. We concur with previous authors, that an osseous screening program should be performed for all patients with newly diagnosed type 1 neurofibromatosis, to identify non-ossifying fibromas and assess the potential for pathological fracture. Moreover, siblings of patients with NF-1 should be screened for multiple NOFs that may carry a high risk of pathological fractures.
Extensive experimental evidence points to neuroinflammation and oxidative stress as major pathogenic events that initiate and drive the neurodegenerative process. Monosodium glutamate (MSG) is a widely used food additive in processed foods known for its umami taste-enhancing properties. However, concerns about its potential adverse effects on the brain have been raised. Thus, the present study investigated the impact of MSG on lipopolysaccharide (LPS)-induced neurotoxicity in rat brains. Wistar rats weighing between 180 g and 200 g were randomly allocated into four groups: control (received distilled water), MSG (received 1.5 g/kg/day), LPS (received 250 µg/kg/day), and LPS + MSG (received LPS, 250 µg/kg, and MSG, 1.5 g/kg). LPS was administered intraperitoneally for 7 days while MSG was administered orally for 14 days. Our results showed that MSG exacerbated LPS-induced impairment in locomotor and exploratory activities in rats. Similarly, MSG exacerbated LPS-induced oxidative stress as evidenced by increased levels of malondialdehyde (MDA) with a concomitant decrease in levels of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), and glutathione-s-transferase (GST) in the brain tissue. In addition, MSG potentiated LPS-induced neuroinflammation, as indicated by increased levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) as well as myeloperoxidase (MPO) and nitric oxide (NO) in the brain. Moreover, MSG aggravated LPS-induced cholinergic dysfunction, as demonstrated by increased activity of acetylcholinesterase (AChE) in the brain. Further, we found a large number of degenerative neurons widespread in hippocampal CA1, CA3 regions, cerebellum, and cortex according to H&E staining. Taken together, our findings suggest that MSG aggravates LPS-induced neurobehavioral deficits, oxidative stress, neuroinflammation, cholinergic dysfunction, and neurodegeneration in rat brains.
PROBLEM TO BE SOLVED: To obtain a liquid agent for internal use presenting high palatability in physical fatigue due to exercise or the like. SOLUTION: This liquid agent for internal use is such one as to be formulated with ascorbic acid at a concentration of 0.5-10 mmol/L. For the ascorbic acid to be used in the present invention, a salt thereof may also be used. The amount of the ascorbic acid to be formulated in the present invention is 0.5-10 mmol/L in terms of concentration, being esp. pref. <=5 mmol/L; if <0.5 mmol/L, sourness of this liquid agent vanishes, while if >10 mmol/L, improvement in its palatability in physical fatigue becomes impossible; the above-mentioned concentration range is especially low compared to those used in common health drinks/beverages.
Randomized phase II using a two-stage Bayesian optimal phase II two-arm design (BOP2). Patients are randomized 1:1 to either the monotherapy or combination arms. This requires 42 patients (21 per treatment arm) in stage I for each race-based cohort. If the no. of response in experimental - no. of response in control is no greater than -1, the trial is early stopped at stage I for futility. Otherwise, additional 42 patients for each race-based cohort will be enrolled and randomized to the study in stage II.
Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.
The sample with CP will be selected from individuals attending the dental clinics of the Prince Sultan bin Abdulaziz Humanitarian city (SBAHC). The control patients will be selected from the dental clinics of the Riyadh Colleges of Dentistry and Pharmacy and be matched to the CP patients for age, gender and extent of dental problems. The sample will comprise of 20 patients with CP and 20 verbal controls.The oral health of all children will be recorded using WHO examination criteria .The teeth will be examined using WHO category II criteria - clinical examination with lighting and without radiographs.aliva will be collected from the children using the passive drool method and stored in sterile plastics collection tubes. The collected sample will be stored at -600C until they can be analyzed. The cytokine profile of the saliva sample will be analyzed using an ELISA kit for total cytokine profile (Luminex Performance Human Cytokine Panel A, LUH000, R\&D systems) to measure cytokines IL-1 alpha, IL-1 beta, IL-8, and TNF-alpha. The pain perception of the verbal control group will be recorded using the validated Arabic version of the short form of the McGill Pain Questionnaire. The children will also indicate the extent of the pain using the Wong Baker Faces ™ pain perception scale.Normality of the total cytokine levels will be tested using the Shapiro-Wilkes Test. The Mann Whiney U test will be used to compare the cytokine profile the CP and control group. The spearman correlation will be used to explore the relationship between the reported pain and cytokine profile levels. If found to be significant an initial cytokine-pain map will be proposed.
The invention discloses a method for killing goat cropping insects. The method for killing goat cropping insects comprises the following operating steps: picking ripened local tomatoes, cleaning, airing, triturating to a pasty state, and smearing the triturated tomatoes on wounded parts of a goat once a day. Five days is a treatment course. By the above method, goat cropping insects can be killed effectively, and the effective rate is 93-95%. After the drug is smeared for 10 days, new fluff grows at bald spots of the goat's original fur areas. In addition, the method has no side effect. In the vast rural areas of our country, it is easy to pick tomatoes in summer. Thus, costs are low. The method is especially suitable for remote rural areas.